



May 28, 2021

The Manager - Listing
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

The Manager - Listing
BSE Limited
Corporate Relationship Dept., 1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

Dear Sir(s),

Sub: Change in business relationship and Discontinuation of the distribution services under the terms of the Distribution Agreement between AstraZeneca Pharma India Limited and Sun Pharma Laboratories Limited for Dapagliflozin and its combinations in India.

We refer to our announcement of March 23, 2016, wherein we had informed about the Distribution Services Agreement entered into between AstraZeneca Pharma India Limited (AstraZeneca India) and Sun Pharma Laboratories Limited (Sun Pharma) for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India. Under the said Agreement, Sun Pharma promoted and distributed Dapagliflozin under the brand name "Oxra®". Sun Pharma also gained the rights to promote and distribute the combination of Dapagliflozin with Metformin under the brand name "Oxramet®" and the combination of Dapagliflozin and Saxagliptin under the brand name "Oxraduo®".

AstraZeneca India and Sun Pharma have discontinued its existing Distribution Services Agreement signed in 2016 by entering into a Transition Supply Agreement with effect from 28th May 2021. Under the Transition Supply Agreement, Sun Pharma will continue to promote and distribute Dapagliflozin and the combinations of Dapagliflozin with Metformin under the brand Oxra and Oxramet until such period of time as mutually agreed between the parties, post which all supplies to Sun Pharma from AstraZeneca India shall cease.

AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names "Forxiga®" "Xigduo®" and "Qtern®" respectively.

We request you to take the above submissions on records.

For AstraZeneca Pharma India Limited

Pratap Rudra
Company Secretary & Legal Counsel

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628